Gapping up
In reaction to earnings/guidance:
- CLF +6.2%, BHVN +4.3%, OPRX +3%, CADE +2.6%, KMB +1.7%, PHG +1.1%
M&A news:
- TSIA +82.6% (TS Innovation Acquisitions and Latch to merge and become publicly listed company)
- IACA +29.3% (ION Acquisition Corp: Taboola to become NYSE listed at an implied $2.6 bln valuation via a merger with ION Acquisition Corp)
- WPF +9.1% (Foley Trasimene Acquisition Corp. and Alight Solutions (ALIT) confirm merger)
- LCY +2.6% (Landcadia Holdings III and HMAN Group Holdings entered into merger agreement that will result in Hillman becoming a publicly listed company named Hillman Solutions Corp with ticker "HLMN") .
Other news:
- EXPR +125.1% (extends momentum after surging by +52% during Friday's session)
- SPRQ +50% (Sunlight Financial to list on NYSE through merger with Apollo (APO) -Affiliated Spartan Acquisition Corp. II)]
- AUPH +42% (receives FDA approval for LUPKYNIS)
- GME +40.6% (continued squeeze)
- AMC +36.5% (raises $917 mln of fresh investment capital since mid-December of 2020; increased liquidity should allow the company to make it through this winter; also entered into an equity distribution agreement sell up to 50,000,000 shares of Class A common stock through an "at-the-market" offering program) GEVO +16.7% (extends momentum after surging by +13% during Friday's session)
- NCTY +15.4% (signed five legally binding MOUs w/ 5 Bitcoin mining machine owners to purchase Bitcoin mining machines by the issuance of Class A ordinary shares)
- DTIL +9.1% (received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering PBCAR19B, a next-generation, stealth cell, CD19 product candidate for patients with relapsed/refractory (R/R) Non-Hodgkin Lymphoma)
- LX +6.1% (achieves 2020 loan origination target)
- ABEO +3.8% (announces successful type B meeting with FDA for pivotal phase 3 VIITAL study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa)
- CLPT +2.3% (files for $120 mln mixed securities shelf offering)
- CNNE +2.2% (announces $250 million investment in Foley Trasimene Acquisition Corp. (WPF) and Alight Solutions Merger)
- KRNY +1.6% (authorizes 5% stock repurchase plan)
- ARWR +1.1% (files IND for phase 2b study of ARO-ANG3 for treatment of mixed dyslipidemia)
- AZN +0.8% (reports Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib; receives approval in Japan for treatment of relapsed or refractory chronic lymphocytic leukaemia)
Analyst comments:
- CNST +3.9% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- REGN +3.9% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- MOS +2% (upgraded to Buy from Neutral at Citigroup)
- AEO +1.6% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- CAKE +1% (upgraded to Neutral from Underweight at JP Morgan)
- MED +1% (upgraded to Buy from Hold at Jefferies)
- CRM +0.8% (upgraded to Hold from Sell at Loop Capital)